Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.56 |
| ▸ | BTK | Q06187 | 3/20 | 0.47 |
| ▸ | FYN | P06241 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14471392 | 0.92 | SRC (0.51) | SRCBTKFYNHDAC1PDGFRB | |
| SCHEMBL14471388 | 0.84 | SRC (0.48) | SRCBTKFYNKDRPIK3CD | |
| SCHEMBL14471396 | 0.80 | SRC (0.43) | SRCBTKFYNHDAC1PDGFRB | |
| SCHEMBL28409284 | 0.78 | BTK (0.63) | SRCBTKFYNLYNBLK | |
| SCHEMBL28412028 | 0.77 | BTK (0.62) | SRCBTKFYNLYNBLK | |
| SCHEMBL28412220 | 0.77 | BTK (0.60) | SRCBTKFYNLYNBLK | |
| SCHEMBL13160649 | 0.77 | SRC (0.45) | SRCBTKFYNHDAC1PDGFRB | |
| SCHEMBL28409282 | 0.76 | BTK (0.61) | SRCBTKFYNLYNBLK | |
| SCHEMBL13183365 | 0.76 | SRC (0.57) | SRCBTKFYNLYNBLK | |
| SCHEMBL28415210 | 0.76 | BTK (0.62) | SRCBTKFYNLYNBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | RHODE ISLAND BOARD OF EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | DSTYK, SRC, PTK2B | SRC 2/4885BTK 28/4885FYN 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.